HTA ID Drug Brand Indication Assessment status Date
- Levofloxacin Quinsair® For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis. Rapid Review Complete 2nd March 2016
- Levonorgestrel intrauterine delivery system LNG IUS 12 Kyleena® For contraception for up to 5 years. Rapid Review Complete 16th March 2017
- Levonorgestrel Intrauterine System Levosert® For contraception and for the treatment of heavy menstrual bleeding. Rapid Review Complete 23rd October 2019
- Levonorgestrel intrauterine system LNG-IUS Jaydess® For contraception for up to three years. Rapid Review Complete 26th March 2013
- Lidocaine 5% plasters Versatis® For the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). Assessment process complete 24th September 2015
- Linaclotide Constella® For the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. Rapid Review Complete 28th June 2013
- Linagliptin Trajenta® For treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Rapid Review Complete 6th September 2011
23068 Linzagolix Yselty® Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Pre submission consultation scheduled 7th March 2024
- Lipegfilgrastim Lonquex® For reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Rapid Review Complete 24th September 2013
23080 Lipegfilgrastim Lonquex® Lipegfilgrastim is indicated in adults and in children two years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lipegfilgrastim is currently reimbursed on High Tech Drug Arrangement for use in adults and reimbursement is sought for children two years of age and older. Rapid Review Complete 27th February 2024
- Liposomal daunorubicin and cytarabine Vyxeos Liposomal® For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes. Assessment process complete 16th April 2020
- Liquid Paraffin Ointment VitA-POS Opthalmic® For the treatment of mild to moderate form of dry eye. Rapid Review Complete 31st January 2014
24001 Liraglutide Saxenda® Liraglutide is indicated as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: • obesity (body mass index (BMI) corresponding to ≥30 kg/m2 for adults by international cut-off points) and • body weight above 60 kg* Rapid Review Complete 9th February 2024
19039 Liraglutide Saxenda® As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is,  as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease. Assessment process complete 10th February 2021
- Liraglutide Victoza® For treatment of adults with type 2 diabetes mellitus. Assessment process complete 7th March 2019
- Lisdexamfetamine dimesylate Tyvense® For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Rapid Review Complete 28th February 2013
__ __ __ __ __ 7th August 2014
- Lomitapide Lojuxta® As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Rapid Review Complete 15th September 2014
23053 Loncastuximab tesirine Zynlonta® Loncastuximab tesirine (Zynlonta®) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. Rapid Review Complete 1st September 2023
- Lorlatinib Lorviqua® As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on: (i) alectinib or ceritinib as the first ALK-targeted treatment, or (ii) crizotinib and at least one other ALK-targeted treatment. Rapid Review Complete 25th June 2019
21071 Lorlatinib Lorviqua® As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Rapid Review Complete 13th January 2022
- Lornoxicam Xefo® For the short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis Rapid Review Complete 7th July 2011
- Loteprednol Lotemax 0.5% eye drops suspension For treatment of post-operative inflammation following ocular surgery. Rapid Review Complete 5th December 2011
- Loxapine inhalation powder Adasuve® For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Rapid Review Complete 28th July 2016
- Lumacaftor/ivacaftor Orkambi® For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. Assessment process complete 14th March 2024
- Lutetium (177Lu) Oxodotreotide Lutathera® For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. Assessment process complete 11th February 2020
23002 Lutetium (177Lu) vipivotide tetraxetan Pluvicto® Lutetium (177Lu) vipivotide tetraxetan in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. NCPE assessment ongoing 5th February 2024
22062 Macimorelin acetate Ghryvelin® For the diagnosis of growth hormone deficiency (GHD) in adults. Rapid Review Complete 20th October 2023
- Macitentan Opsumit® Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III. Rapid Review Complete 31st January 2014
- Magnesium Aspartate Dihydrate Magnaspartate® For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years.   Rapid Review Complete 14th May 2019
- Mannitol Dry Powder Bronchitol® Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF) Assessment Process Complete 29th April 2019
22069 Maribavir Livtencity® For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant. Rapid Review Complete 14th March 2024
23028 Mavacamten Camzyos® Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. Full HTA submission received from Applicant 20th December 2023
- Melatonin Circadin® Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia. Full HTA Assessment 21st October 2008
22048 Melatonin Slenyto® For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient. Rapid Review Complete 9th August 2022
23067 Melphalan flufenamide Pepaxti® Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation. Rapid Review Complete 15th December 2023
- Mepolizumab Nucala® Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients. Assessment Process Complete 1st March 2017
- Mepolizumab Nucala® Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over. Rapid Review Complete 5th November 2019
20007 Meropenem/vaborbactam Vaborem® Is indicated for the treatment of the above infections in adults. Rapid Review Complete 2nd April 2020
- Methoxyflurane Penthrox® For the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses. Rapid Review Complete 18th December 2015
19049 Methyl aminolevulinate Metvix® For the treatment of: thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp, when other therapies are considered less appropriate; superficial and/or nodular basal cell carcinoma unsuitable for other available therapies; and squamous cell carcinoma in situ (Bowen´s disease) when surgical excision is considered less appropriate. Rapid Review Complete 18th December 2019
- Midostaurin Rydapt® Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. Assessment Process Complete 5th December 2019
- Midostaurin Rydapt® Midostaurin is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). Suspended 16th October 2018
- Mifamurtide Mepact® For the treatment of osteosarcoma. Rapid Review Complete 13th July 2010
- Migalastat Galafold® For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation. Assessment Process Complete 1st June 2017
- Mirabegron Betmiga® Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Rapid Review Complete 12th March 2013
23040 Mirikizumab Omvoh® Mirikizumab (Omvoh®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. Rapid Review Complete 24th August 2023
- Modified Release Hydrocortisone Plenadren® For the treatment of adrenal insufficiency in adults. Assessment process complete 1st January 2018
20061 Mogamulizumab Poteligeo® For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. NCPE Assessment Process Complete 6th July 2023
21060 Molnupiravir Lagevrio® For the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. Rapid Review Complete 24th December 2021